The DOI matches its Crossref record; 316 of the 318 references it cites were found in a registry or an index, and 1 are not checked yet.
Combination strategies to maximize the benefits of cancer immunotherapy
Open accessAbstract
Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy (ACT) have revolutionized cancer treatment, especially in patients whose disease was otherwise considered incurable. However, primary and secondary resistance to single agent immunotherapy often results in treatment failure, and only a minority of patients experience long-term benefits. This review article will discuss the relationship between cancer immune response and mechanisms of resistance to immunotherapy. It will also provide a comprehensive review on the latest clinical status of combination therapies (e.g., immunotherapy with chemotherapy, radiation therapy and targeted therapy), and discuss combination therapies approved by the US Food and Drug Administration. It will provide an overview of therapies targeting cytokines and other soluble immunoregulatory factors, ACT, virotherapy, innate immune modifiers and cancer vaccines, as well as combination therapies that exploit alternative immune targets and other therapeutic modalities. Finally, this review will include the stimulating insights from the 2020 China Immuno-Oncology Workshop co-organized by the Chinese American Hematologist and Oncologist Network (CAHON), the China National Medical Product Administration (NMPA) and Tsinghua University School of Medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Accumulating evidence indicates that chemotherapy, radiotherapy, angiogenesis inhibitor, stimulator of interferon genes (STING) agonist, fecal microbiota transplantation (FMT), epigenetic modulators, or other immunomodulators could synergize α-PD-1/PD-L1, by enhancing cancer antigen release, APC function, or effector activity [22–31].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 1×
“Two coronavirus (COVID-19) mRNA vaccines approved in the US are both RNA vaccines formulated in lipid nanoparticles [285, 286].”
BackgroundEfficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · cited 1×
“Two coronavirus (COVID-19) mRNA vaccines approved in the US are both RNA vaccines formulated in lipid nanoparticles [285, 286].”
BackgroundCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · cited 1×
“Pembrolizumab + pemetrexed /platinum First‐line non‐squamous NSCLC May 10, 2017 [50, 296]”
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Research works printed but not linked: 1
- Shalabi H, Shah NN, Fry TJ, Yates B, Delbrook C, Yuan C, Stetler-Stevenson M, Ramakrishna S. Intensification of lymphodepletion optimizes CAR re-treatment efficacy. Blood. 2017;130(Supplement 1):3889–3889.
Cited by
Sorted by citations
Items 301–400 of 663
Chen, S., Zhang, L., Lin, H., Liang, Y., & Wang, Y. (2022) · Biomolecules · doi:10.3390/biom13010058 · Cited by 9
Sun, W., Yuan, Y., Chen, J., Bao, Q., Shang, M., Sun, P., & Peng, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1259231 · Cited by 10
Huang, S., Zhou, C., Song, C., Zhu, X., Miao, M., Li, C., Duan, S., & Hu, Y. (2024) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2024.100901 · Cited by 9
A Review of Practice-Changing Therapies in Oncology in the Era of Personalized Medicine
Capella, M. P., & Esfahani, K. (2024) · Current Oncology · doi:10.3390/curroncol31040143 · Cited by 8
Ka, H. I., Mun, S. H., Han, S., & Yang, Y. D. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.056860 · Cited by 8
Deng, H., Li, Q., Wang, B., Hong, Y., Sun, S., Li, Z., Pan, W., Zhao, Q., Dai, H., Lu, J., et al. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102285 · Cited by 8
Self-citationAlrumaihi, F., Alromaihi, R. A., Kumar, V., & Anwar, S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47121056 · Cited by 8
Baek, J., Lee, S., Kim, D., Jin, H. K., & Kim, E. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04277-9 · Cited by 8
Yip, R., Arnolda, G., Lamprell, K., Easpaig, B. N. G., Chittajallu, R., Delaney, G. P., Olver, I., Liauw, W., & Braithwaite, J. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007555 · Cited by 8
Yin, X., Liu, X., Ren, F., & Meng, X. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03712-7 · Cited by 8
Ouologuem, L., & Bartel, K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1389194 · Cited by 8
A comprehensive review of PRAME and BAP1 in melanoma: Genomic instability and immunotherapy targets
Aljabali, A. A. A., Tambuwala, M. M., El‐Tanani, M., Hassan, S. S., Lundstrom, K. H., Mishra, V. K., Mishra, Y., Hromić-Jahjefendić, A., Redwan, E. M. M. M., & Uversky, V. N. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111434 · Cited by 8
Patel, M. R., Falchook, G. S., Wang, J. S.-Z., Imedio, E. R., Kumar, S., Miah, K., Mugundu, G. M., Jones, S. F., Spigel, D. R., & Hamilton, E. P. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01110-8 · Cited by 8
Immune Checkpoint Inhibitors Impact Fertility: A Review
Shabir, I., & Foster, C. (2025) · Reviews on Recent Clinical Trials · doi:10.2174/0115748871340496250130054721 · Cited by 8
An overview of Sgc8 aptamer as a potential theranostic agent for cancer with PTK7 oncogenic target
Wang, Y., Yuan, Z., Zhai, L., Lv, M., Iqbal, H., Ur-Rehman, U., Ning, X., Jin, Z., Yi, Z., & Xiao, R. (2025) · Science Progress · doi:10.1177/00368504251325385 · Cited by 8
Maheen, S., Awan, M. S., Abbas, G., Shah, S., Khan, I. U., Khan, I. U., Almehizia, A. A., Khan, M. A., Majeed, A., Razzaq, S., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142070 · Cited by 8
Magnetic hyperthermia-based therapies for cancer targeting: current progress and future perspectives
Rana, P., Garima, G., Devi, S., Kaur, G., Singh, S. K., & Mittal, N. (2025) · Medical Oncology · doi:10.1007/s12032-025-03020-9 · Cited by 8
Wei, W., Liu, C., Wang, C., Wang, M., Jiang, W., Zhou, Y., & Zhang, S. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1016797 · Cited by 8
Zhao, G., Jiang, Y., Ma, P., Wang, S., Nie, G., & Li, N. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.12.007 · Cited by 8
Wang, M., Zhang, J., Tang, J., Cai, X., Dou, R., Guo, C., Hu, Y., & Chen, J. (2023) · JCIS Open · doi:10.1016/j.jciso.2023.100081 · Cited by 8
Raphael, J., Richard, L., Lam, M., Blanchette, P., Leighl, N. B., Rodrigues, G., Trudeau, M., & Krzyzanowska, M. K. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad090 · Cited by 8
Saffarzadeh, N., Foord, E., O'Leary, E., Mahmoun, R., Hansen, T. B., Levitsky, V., Poiret, T., & Uhlin, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05049-2 · Cited by 8
Liu, Q., Lin, H., Han, H.-W., Yang, C., Liu, C., & Zhang, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.803454 · Cited by 8
Precision epigenetic therapies in oncology
Chaudhary, A., Orchard, K. J. A., Salani, F., Partsou, T., Eccleston, M., Bocci, G., Italiano, A., & Crea, F. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10288-w · Cited by 7
Xie, H., Ji, T., Zhang, C., Cheng, M., Wang, R., Wu, Y., Wang, J., Wang, H., Yang, J., Xu, S., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf219 · Cited by 7
Progress in the Application of Nanomaterials in Tumor Treatment
He, X., Wang, L., Zhang, T., & Lu, T. (2025) · Biomedicines · doi:10.3390/biomedicines13112666 · Cited by 7
Self-citationYu, J., Qiu, Z., Yan, S., Lin, A., & Li, Y. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb02282g · Cited by 7
Ghaffari, K., Hasan-Abad, A. M., Etedali, M., Alizadeh, S., & Ghasemi, A. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.101074 · Cited by 7
Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy
Wu, X., Sun, M., Li, L., Wang, J., & Wan, S. (2026) · Advanced Science · doi:10.1002/advs.202521936 · Cited by 8
Cordycepin Augments the Efficacy of Anti-PD1 against Colon Cancer
Chang, W., Chen, Y., Lin, C.-P., Wang, C., Shieh, H.-R., Chi, C., Tsai, T., & Chen, Y.-J. (2024) · Biomedicines · doi:10.3390/biomedicines12071568 · Cited by 7
Zhang, T., Li, W., Chen, Q., He, W.-P., Sun, J., Li, D., Wang, Q., & Duan, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1508028 · Cited by 7
Self-citationPallathadka, H., Jabir, M. S., Rasool, K. H., Hanumanthaiah, M., Sharma, N., Pramanik, A., Rab, S. O., Jawad, S. F., Oghenemaro, E. F., & Mustafa, Y. F. (2024) · Human Immunology · doi:10.1016/j.humimm.2024.111221 · Cited by 7
Roy, A. A., Pandey, A. P., Dhas, N. L., Hegde, M. M., Parekh, H. S., Andugulapati, S. B., Nandakumar, K., Rao, B. S. S., & Mutalik, S. (2025) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/adpp/1847197 · Cited by 6
Hutchings, M., Korfi, K., Montesinos, P., Santoro, A., Hou, H., Martínez‐Sánchez, P., Vives, S., Galimberti, S., Chen, T., Frigeni, M., et al. (2025) · Blood Neoplasia · doi:10.1016/j.bneo.2025.100110 · Cited by 7
Zhang, X., Kang, H., Li, B., Xiong, Y., Zheng, S., Zhang, D., Liu, Y., Li, S., Liu, Y., Liu, H., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03231 · Cited by 7
Self-citationThe way of interaction between Vγ9Vδ2 T cells and tumor cells
Zhang, T., Wang, J., Zhao, A., Xia, L., Jin, H., Xia, S., & Shi, T. (2022) · Cytokine · doi:10.1016/j.cyto.2022.156108 · Cited by 7
Self-citationLee, Y., Siao, C.-L., Yang, H.-Y., Lai, Y., Liang, Y., Chen, Y.-F., & Wu, M.-C. (2023) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2023.102486 · Cited by 7
Calado, R., Mendes, B. B., Conniot, J., Ravasco, J. M. J. M., Sobral, D., Ferreira, C., Ferreira, R., Rodrigues, J. C., Santos, D., Duarte, S., et al. (2024) · Matter · doi:10.1016/j.matt.2024.04.002 · Cited by 7
Combination Immunotherapy with Vaccine and Oncolytic HSV Virotherapy Is Time Dependent
Totsch, S. K., Ishizuka, A. S., Kang, K., Gary, S. E., Rocco, A., Fan, A. E., Zhou, L. N., Valdes, P. A., Lee, S., Li, J., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0873 · Cited by 7
Xiao, X., Zheng, Y., Wang, T., Zhang, X., Fang, G., Zhang, Z., Zhang, Z., & Zhao, J. (2024) · Nanoscale Advances · doi:10.1039/d4na00079j · Cited by 7
Cao, L., Tang, D., Yu, Z., Shen, Y., Wang, Y., Li, Y., Chen, J., Liu, Z., Yin, J., Xiao, H., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202403225 · Cited by 7
Cai, F., Li, Y., Liu, H., & Luo, J. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2400025 · Cited by 7
Self-citationRecent Progress of Metal-Based Nanozymes for Biomedical Applications
Chen, B., Dai, Y., Yang, S., Zhou, X., Guan, Y., Ding, Z., Wang, Z., Xu, M., Yuwen, L., & Wang, L. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c12850 · Cited by 6
Liu, R., Yu, H.-H., Li, W.-R., Wu, J.-S., Zhang, J., Luo, J., Pang, Y., Chen, Y., Yao, Y.-D., Lin, R., et al. (2026) · 中国科学通报：英文版 · doi:10.1016/j.scib.2026.01.022 · Cited by 6
Bioactive glasses in the new era: Technological advances and targeted therapies
Gupta, A., Kurian, A. G., Jain, S. K., Singh, R. K., & Kim, H. (2026) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2026.103835 · Cited by 6
Kaliyamoorthi, K. (2026) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2026.106978 · Cited by 6
Mirala, F., Kashkooli, F. M., & Soltani, M. (2026) · Microvascular Research · doi:10.1016/j.mvr.2026.104955 · Cited by 6
Platinum Twin and Triplet Drugs Improve Chemoimmunotherapy
Hao, Y., Li, R., Pan, W., Tian, S., & Min, Y. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00792 · Cited by 6
Zhu, Y., Zhang, X., Chen, Y., Liu, Q., Yang, J., Fan, X., Song, H., Cheng, Z., & Liu, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27155 · Cited by 6
Wang, M., Wan, Q., Wang, C., Jing, Q., Nie, Y., Zhang, X., Chen, X., Yang, D., Pan, R., Li, L., et al. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-04966-6 · Cited by 6
Yang, R., Gu, C., Xie, F., Hong, S., Herth, F. J. F., & Sun, J. (2024) · Respiration · doi:10.1159/000538383 · Cited by 6
Yang, Y., Yan, F., & Shi, Z. (2024) · Chemical Research in Chinese Universities · doi:10.1007/s40242-024-4108-3 · Cited by 6
Li, F., Wang, J., Liu, T., Yang, W., Li, Y., Sun, Q., Yan, J., & He, W. (2024) · Small · doi:10.1002/smll.202404892 · Cited by 6
Deng, X., & Liu, J. (2024) · Translational Breast Cancer Research · doi:10.21037/tbcr-24-21 · Cited by 6
Li, Y., Zhang, M., Hu, Y., Du, B., Mo, Y., He, T., Zhao, M., Li, B., Xia, J., Huang, Z., et al. (2025) · Technology in Cancer Research & Treatment · doi:10.1177/15330338251351109 · Cited by 6
Chen, Z., Fang, X., Jia, L.-J., Feng, Y. J., Cheng, J.-H., Luo, S., Wen, S., Wei, J., Ma, S., Guo, X., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115247 · Cited by 6
Liu, W., Jiang, H., Xu, J., & Guo, Y. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.146529 · Cited by 6
Kim, Y., & Lee, H.-M. (2023) · Cells · doi:10.3390/cells12222593 · Cited by 6
Wang, Y., Hao, Q., Nie, J., Dai, L., Hu, W., Zhang, J., Chen, X., Ma, X., Tian, G., Han, J., et al. (2024) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001569 · Cited by 6
Yang, J., Xiong, X., Zheng, W., Xu, H., Liao, X., Wei, Q., & Yang, L. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001939 · Cited by 6
Muzammal, M., Awan, M., Mukhtar, A., Mohsin, M., & Qamar, M. A. (2024) · ChemistrySelect · doi:10.1002/slct.202403554 · Cited by 6
SHR-1806, a robust OX40 agonist to promote T cell-mediated antitumor immunity
Zhang, J., Zhou, L., Sun, X., Lin, Y., Yuan, J., Yang, C., & Liao, C. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2426305 · Cited by 6
Nanobots: The current scenario
Gupta, S., Tomar, A., Manohar, D. L., & Panwar, P. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104652 · Cited by 6
Kim, S., Lee, H.-J., Lee, S., Chung, J. E., Oh, S. J., Song, K., Cho, E., Son, M. K., Kwon, H., Kim, S.-J., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0379 · Cited by 6
Ren, X., Guo, A., Geng, J., Chen, Y., Wang, X., Zhou, L., & Shi, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1544104 · Cited by 6
Cao, Q., Zhang, Y., Cheng, C., Wang, X., Fan, P., Huang, J., & Dai, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-10290-w · Cited by 6
NMI: a potential biomarker for tumor prognosis and immunotherapy
He, T., Qiao, Y., Yang, Q., Chen, J., Chen, Y., Chen, X., Hao, Z., Lin, M., Shao, Z., Wu, P., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1047463 · Cited by 6
Zheng, C.-S., Huang, W., Xia, H., Mi, J., Li, Y.-Q., Liang, H., Zhou, L., Lu, Z.-X., & Wu, F. (2023) · APOPTOSIS · doi:10.1007/s10495-023-01884-8 · Cited by 6
Ren, Q., Zhang, P., Zhang, S., Chen, W., Chi, H., Wang, W. T., Zhang, W., Lin, H., & Yu, Y. (2023) · Aging · doi:10.18632/aging.205090 · Cited by 6
Oncolytic virus: A catalyst for the treatment of gastric cancer
Wang, J., Du, L., & Chen, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1017692 · Cited by 7
Lim, S. Y., Kim, L., Kim, H. B., Park, J., Yun, J., & Lim, K. S. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091189 · Cited by 5
Oljačić, S., Popovic-Nikolic, M., Filipić, B., Gagić, Ž., & Nikolic, K. M. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266337668241025061804 · Cited by 5
Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance
Tian, J., Shi, Z., Zhao, L., Liu, P., Sun, X., Long, L., Zang, J., & Xiao, J. (2024) · The Clinical Respiratory Journal · doi:10.1111/crj.70037 · Cited by 5
Silicasomes in Oncology: From Conventional Chemotherapy to Combined Immunotherapy
Arroyo-Nogales, A., Plaza-Palomo, G., Gónzalez‐Larre, J., Jiménez‐Falcao, S., & Baeza, A. (2025) · Molecules · doi:10.3390/molecules30061257 · Cited by 5
Sadegh, R. K., Saleki, K., & Rezaei, N. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114837 · Cited by 5
Wu, L., Qiu, J., Hong, Z., Wang, Q., Li, Q., & Zhou, W. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1685857 · Cited by 5
Zhu, M., Xiong, J., Zhang, R., Yang, X., Sun, W., Yang, Z., Chai, Y., Tao, Y., Zhao, Y., Fan, B., et al. (2026) · Cells · doi:10.3390/cells15020126 · Cited by 5
Pan, J., Chen, S., Jin, L., Chen, K., Ye, Z., & Li, B. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189544 · Cited by 6
Bridging mechanism and clinic: unlocking the full potential of oncolytic virus-based immunotherapy
Hua, X., Tang, H., Liang, K., Li, J., Zhang, X., Shen, L., & ZHANG, C. Z. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02651-4 · Cited by 5
Response Challenges to Cancer Immunotherapies
Al-Janabi, I. I. (2022) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v2i.65 · Cited by 5
Lin, H., Pang, W.-P., Yuan, H., Kong, Y., Long, F., Zhang, R., Yang, L., Fang, Q.-L., Pan, A., Fan, X., et al. (2023) · Aging · doi:10.18632/aging.204870 · Cited by 5
Sano, T., Saito, R., Aizawa, R., Watanabe, T., Murakami, K., Kita, Y., Masui, K., Goto, T., Mizowaki, T., & Kobayashi, T. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02421-y · Cited by 5
Röhnisch, T., Martos-Contreras, M. C., Manoochehri, M., Nogueira, M. S., Bremm, F., Dörrie, J., Christoph, J., Kunz, M., & Schönharting, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1414737 · Cited by 5
Qu, J., Li, Y., Wu, B., Shen, Q., Chen, L., Sun, W., Wang, B., Ying, L., Wu, L. M., Zhou, H., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2371575 · Cited by 5
Darmadi, D., Aminov, Z., Hjazi, A. M., Roopashree, R., Kazmi, S. W., Mustafa, Y. F., Hosseen, B., Sharma, A., Alubiady, M. H. S., & Al‐Abdeen, S. H. Z. (2024) · Experimental Cell Research · doi:10.1016/j.yexcr.2024.114267 · Cited by 5
Chen, R., Lu, Q., Zeng, F., Qin, S., Pan, Y., Liu, Z., Wang, Y., He, B., Qi, W., & Song, Y. (2024) · Materials Today · doi:10.1016/j.mattod.2024.09.002 · Cited by 5
Peng, H., Moore, C., Saha, D., Jiang, S. B., & Timmerman, R. D. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1497351 · Cited by 5
Rattanapisit, K., Suwanchaikasem, P., Bulaon, C. J. I., Guo, S., & Phoolcharoen, W. (2025) · PLoS ONE · doi:10.1371/journal.pone.0316790 · Cited by 5
Song, X., Tong, X., Yang, K., Qi, Y., Liu, W., Sun, Y., Wang, C., Xun, F., Wang, Z., Jiang, M., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108308 · Cited by 5
Wu, M., Liu, J., Liu, L., Yang, Y., Liu, H., Long, Y., Zeng, H., Yuan, S., Xu, R., Liu, H., et al. (2025) · Advanced Science · doi:10.1002/advs.202401230 · Cited by 5
Self-citationChen, Z., Qi, H., Xue, Y., Zhang, Y., Zhang, Z., Xu, S., Liao, S., Zeng, X., Wu, J., Lv, X., et al. (2025) · MedComm – Oncology · doi:10.1002/mog2.70015 · Cited by 6
Optimal Pharmaceutical Management Strategies in Cancer Treatment: Novel Approaches
Alishahi, F., Soudmand, N., Goki, T. G., & Rashidoleslami, T. S. (2025) · Asian Pacific Journal of Cancer Nursing · doi:10.31557/apjcn.1740.20250308 · Cited by 5
Breaking down barriers: The potential of smarter CAR‐engineered NK cells against solid tumors
Khawar, M. B., Gao, G., Rafiq, M., Shehzadi, A., Afzal, A., Abbasi, M. H., Sheikh, N., Afzal, N., Ashraf, M. A., Hamid, S. E., et al. (2023) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30460 · Cited by 5
ILT4 facilitates angiogenesis in non‐small cell lung cancer
Wang, S., Wang, J., Gong, W., Zhang, F., Chen, X., Xu, H., Han, Y., Fu, X., Wang, L., Li, J., et al. (2024) · Cancer Science · doi:10.1111/cas.16126 · Cited by 5
Podaza, E., Capuano, J. A., Assaad, M. A., Kuo, H., Markowitz, G. J., Irizarry, A., Ravichandran, H., Ackermann, S. E., Kane, T., Manohar, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.05.546622 · Cited by 5
Surface display of two neoantigens on Lactiplantibacillus plantarum
Wiull, K., Holmgren, E., Svensson, S., Eijsink, V. G. H., Grönlund, H., & Mathiesen, G. (2025) · Scientific Reports · doi:10.1038/s41598-025-91180-z · Cited by 4
Yahya, A., Lobelo, P., Eram, A., Hussain, S. A., Badruddin, I. A., Bulay-Og, L. L. D., & Albina, D. O. (2025) · Results in Engineering · doi:10.1016/j.rineng.2025.106002 · Cited by 4
Peng, Z., Xie, L., Zhou, S., & Li, Y. (2025) · MedComm · doi:10.1002/mco2.70432 · Cited by 4
Afzal, O., Enneiymy, M., Bibi, S., Madkhali, H. A., Aldakhil, T., Chagaleti, B. K., Khan, S. G., Riadi, Y., Altharawi, A., & Haggam, R. A. (2026) · Chemical Physics Impact · doi:10.1016/j.chphi.2026.101001 · Cited by 4
Chen, X., Tang, X., Chen, S., Ye, Y., & Mao, F. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1709908 · Cited by 4
Metadata
- Authors
- Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X.
- Affiliations
- Beijing Chao-Yang Hospital, Capital Medical University (CN)
- Duke University (US)
- Johns Hopkins University (US)
- University of Chicago (US)
- New York Medical College (US)
- The Ohio State University (US)
- Harvard University (US)
- Corresponding author
- Li, Zihai
- Pan, Chong-xian
- Venue
- Journal of Hematology & Oncology
- Published
- 2021-09-27
- Volume
- 14
- Issue
- 1
- Pages
- 156-156
- ISSN
- 1756-8722 (ISSN-L)
- PMC
- PMC8475356
- OpenAlex
- W3202901824
- Cited by
- 654
- References
- 318
- Citations by year
- 2026: 78 · 2025: 163 · 2024: 206 · 2023: 127 · 2022: 77 · 2021: 2
- FWCI
- 12.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal of Hematology & Oncology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Touro Scholar (Touro College) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Tsinghua University
- National Cancer Institute (P50CA062924)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- cancer immunotherapy, combination therapy, immune checkpoint blockade, adoptive immunotherapy, immunotherapy resistance, cancer vaccines, virotherapy, cytokine-targeted therapy, combination chemotherapy, radiation therapy combination, combination targeted therapy
- MeSH terms
- Immune Checkpoint Inhibitors, Animals, Combined Modality Therapy, Humans, Immunotherapy, Neoplasms, Cancer Vaccines, Oncolytic Virotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
